Scilex Holding(us:SCLX)

    0.4197

    -8.12%

    Updated on 2024-12-25

    Open:0.4810
    Close:0.4197
    High:0.4837
    Low:0.3952
    Pre Close:0.4568
    Volume:1.38M
    Amount:582095.50
    Turnover:0.62%
    Shares:220.85M
    MarketCap:92.69M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-301103986130132.83%131241
    2024-03-311052811344826.49%192719
    2023-12-31982615825016.34%151820
    2023-09-30972855266118.52%91731
    2023-06-301032097955714.11%202024
    2023-03-3184122012138.33%7642
    2022-12-312392030040.14%11237
    2022-09-3031767024258.21%3316
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31State Street Corp74153366.99%190890.26%
    2024-03-31Blackrock Inc.66896766.30%-115913-1.70%
    2024-03-31Vanguard Group Inc39882653.76%557571.42%
    2024-03-31Millennium Management Llc10666591.01%827697346.37%
    2024-03-31Geode Capital Management, Llc10484090.99%456414.55%
    2024-03-31Goldman Sachs Group Inc8853000.83%725127452.71%
    2024-03-31Northern Trust Corp6820890.64%-4986-0.73%
    2024-03-31D. E. Shaw & Co., Inc.6270380.59%0
    2024-03-31Rafferty Asset Management, Llc6201310.58%0
    2024-03-31Citigroup Inc5297800.50%17323748.59%

    About

    Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
    Address:960 San Antonio Road

    Market Movers